斯库特拉林通过TGF-β1信号通路改善糖尿病病
Bangrui Huang1, Rui Han2, Hong Tan2
1Key Laboratory of Medicinal Chemistry for Natural Resource (Ministry of Education), Yunnan Provincial Center for Research & Development of Natural Products, School of Pharmacy, Yunnan University.
Biological & pharmaceutical bulletin
|October 19, 2023
概括
布雷维斯卡的化合物斯库特拉林通过减少损伤,有效治疗糖尿病病 (DN). 它通过调节参与DN进展的关键信号通路来起作用.
科学领域:
- 药理学 药理学是指药理学的学科.
- 腎臟病學 (nephrology) 是一種醫學.
- 自然产品 化学 化学
背景情况:
- 糖尿病病 (DN) 是糖尿病的一个主要并发症,导致损伤.
- 来自Erigeron breviscapus的布雷维斯卡因显示出治疗DN的潜力.
- 布雷维斯卡在DN中的活性成分和机制尚未完全理解.
研究的目的:
- 研究布雷维斯卡宾成分斯库特拉林对糖尿病病的治疗作用.
- 阐明斯库特拉林在DN中的作用背后的药理机制.
主要方法:
- 在体内诱发链毒素的糖尿病病模型.
- 评估功能和组织学变化.
- 对TGF-β1,Erk和Wnt/β-catenin信号通路的分析.
主要成果:
- 斯库特拉林显著改善了蛋白尿症,球扩张和中基质矩阵积累.
- 斯库特拉林减少了纤维化,并保护了细胞免受损伤.
- 观察到对TGF-β1,Erk和Wnt/β-catenin通路的调节.
结论:
- 在糖尿病病的临床前模型中,scutellarin 显示出显著的保护作用.
- 斯库特拉林的治疗效益包括调节TGF-β1,Erk和Wnt/β-catenin信号传递.
- 斯库特拉林是布雷维斯卡宾的关键活性成分,有可能用于DN治疗.
更多相关视频
07:15Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway
Published on: August 23, 2024
449
06:54Studying TGF-β Signaling and TGF-β-induced Epithelial-to-mesenchymal Transition in Breast Cancer and Normal Cells
Published on: October 27, 2020
13.0K
相关概念视频
01:16TGF - β Signaling Pathway
7.4K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.4K
01:23Dipeptidyl Peptidase 4 Inhibitors
192
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
192